The goal of the University of Colorado NCI Comprehensive Cancer Center (UCCC) K12 program is to train successful patient-oriented clinical and basic research investigators who can work effectively with each other in a translational, team research setting. These researchers will be able to independently design, implement and manage all phases of clinical trials research with an emphasis on translation of laboratory findings into clinical applications, as well as facilitating laboratory studies into the basic mechanisms of poorly understood clinical phenomena. The specific objectives are to: 1) Provide a flexible career development program for oncology medical doctors and Ph.D. nurses who have completed their clinical training and who are committed to a translational clinical cancer research career in an academic setting, as well as basic scientists committed to patient-oriented research;2) Foster interdisciplinary training, communication and interaction through multiple mentoring of program scholars;3) Create an opportunity of ongoing mentorship to support these junior faculty scholars after their formal career development program ends to ensure their successful transition to clinical research independence. Strong clinical and scientific mentors in all oncology disciplines and basic researchers will collaborate to train the Scholars. A multidisciplinary Advisory Committee will oversee the program together with Program Leader. Madeleine A. Kane, MD, Ph.D. The overall training period will last from two to seven years and will include didactics, critical evaluation of the medical literature in the subject area, clinical experience, scientifically-based clinical research training and a basic research experience for clinicians. Didactic coursework will be provided from the K30 Award supporting the Clinical Scientist Training Program enhanced by lecture series, seminars, journal clubs, workshops, attendance at national meetings and opportunities for scholars to present research results. Responsible conduct of research will be emphasized through various training experiences. Each scholar is required to submit an NIH style grant application within the last year of training. Six MD Scholars in five oncology disciplines received training during the first five-year award to UCCC. Five remain immersed in clinical-translational human-oriented research, four as UCDHSC faculty, three of whom have been promoted. Productivity includes 70 papers, 23 as first or senior author, multiple abstract presentations, 50 clinical trials initiated as PI or co-Pi, and 13 grant awards, 6 of which were by major sponsors. This K12 program has thus been highly successful in reaching the ultimate goal of producing human-oriented oncology research investigators who successfully and independently conduct solid and innovative clinical oncology research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA086913-09
Application #
7925626
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
2000-09-18
Project End
2013-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
9
Fiscal Year
2010
Total Cost
$118,515
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Courtney, Kevin D; Infante, Jeffrey R; Lam, Elaine T et al. (2018) Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2? Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 36:867-874
Lam, Elaine T; Eckhardt, S Gail; Messersmith, Wells et al. (2018) Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther 17:215-221
Kessler, Elizabeth R; Su, Lih-Jen; Gao, Dexiang et al. (2018) Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer. Integr Cancer Ther 17:1103-1108
Bhatia, Shilpa; Griego, Anastacia; Lennon, Shelby et al. (2018) Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor. Mol Cancer Ther 17:2049-2059
Kessler, E R; Gao, D; Flaig, T W et al. (2017) Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. Ann Oncol 28:668
Campbell, Warren G; Jones, Bernard L; Schefter, Tracey et al. (2017) An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol 124:168-173
Dorris, Kathleen; Liu, Chunyan; Li, Dandan et al. (2017) A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatr Blood Cancer 64:
Carrasco Jr, Alonso; Caldwell, Brian T; Cost, Carrye R et al. (2017) Reliability of intraoperative frozen section for the diagnosis of renal tumors suspicious for malignancy in children and adolescents. Pediatr Blood Cancer 64:
Campbell, Warren G; Miften, Moyed; Olsen, Lindsey et al. (2017) Neural network dose models for knowledge-based planning in pancreatic SBRT. Med Phys 44:6148-6158

Showing the most recent 10 out of 100 publications